Researcher
Gil Verschelden
- Keywords:Medicine
Affiliations
- Intensive Care (Department)
Member
From1 Jan 2024 → Today - Emergency Medicine (Department)
Member
From1 Oct 2023 → 31 Dec 2023 - Internal medicine (Department)
Member
From1 Oct 2021 → 30 Sep 2023 - Internal medicine (Department)
Member
From1 Aug 2017 → 30 Sep 2019 - Faculty of Medicine and Pharmacy (Faculty)
Member
From1 Oct 2015 → 7 Sep 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From26 Jul 2011 → 24 Jun 2015
Publications
1 - 9 of 9
- Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools(2023)
Authors: Gil Verschelden, Maxim Noeparast, Laura Vandervore, A Stoefs, Margo Olbrecht, Eveline Van Honacker, Katleen Vandamme, Kristof Vandoorslaer, Thomas Demuyser, Denis Pierard, et al.
- Analysis of a Combined HBHA and ESAT-6-Interferon-γ-Release Assay for the Diagnosis of Tuberculous Lymphadenopathies(2023)
Authors: Françoise Mascart, Maya Hites, Emmanuelle Watelet, Gil Verschelden, Christelle Meuris, Jean-Luc Doyen, Anne Van Praet, Audrey Godefroid, Emmanuelle Petit, Mahavir Singh, et al.
- Optimization of the Transwell® assay for the analysis of neutrophil chemotaxis using flow cytometry to refine the clinical investigation of immunodeficient patients(2022)
Authors: Maïlis Lauwers, Gil Verschelden, Caroline Boero, Manon Baleine, Véronique Kerrels, Brigitte Cantinieaux
- Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy)(2022)
Authors: Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, Alpha Diallo, Minh-Patrick Lê, Gilles Peytavin, Thérèse Staub, et al.
Pages: 209-221 - Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection(2022)
Authors: A Poncelet, Gil Verschelden, Martin Colard, M. Hildebrandt, Nicolas Yin, Charlotte Michel, David Grimaldi, Virginie De Wilde
Pages: 253-255 - Presumed Urinary Tract Infection in Patients Admitted with COVID-19: Are We Treating Too Much?(2021)
Authors: Johan Van Laethem, Stephanie C M Wuyts, Jan Pierreux, Lucie Seyler, Gil Verschelden, Thibault Depondt, Annelies Maurits Y Meuwissen, Patrick Lacor, Denis Pierard, Sabine D Allard
- Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID)(2021)
Authors: Jozefien Declercq, Karel F A Van Damme, Elisabeth De Leeuw, Bastiaan Maes, Cedric Bosteels, Simon J Tavernier, Stefanie De Buyser, Roos Colman, Maya Hites, Gil Verschelden, et al.
Pages: 1427-1438 - Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients(2021)
Authors: Gil Verschelden, Maxim Noeparast, Maryam Noparast, Mathijs Goossens, Maïlis Lauwers, Frédéric Cotton, Charlotte Michel, Cleo Goyvaerts, Maya Hites
- Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib(2016)
Authors: Maxim Noeparast, Erik Teugels, Philippe Giron, Gil Verschelden, Sylvia De Brakeleer, Lore Decoster, Jacques De Grève
Pages: 60094-60108